Breaking News

Juniper Pharma Adds VP Role

March 30, 2016

Weiss to head Medical Affairs and Clinical Development

Herman Weiss, MD, MBA, FACOG, has been appointed to the newly-created role of vice president, Medical Affairs and Clinical Development at Juniper Pharmaceuticals, Inc.
 
Dr. Weiss will work with chief medical officer Dr. Bridget Martell to support the development of Juniper's product portfolio, providing medical, clinical and regulatory expertise for current and future product candidates leveraging its delivery technologies.
 
"We are thrilled to have recruited such a medical talent to Juniper Pharmaceuticals as we advance our high-value pipeline to address acute and chronic women's health conditions into later stages of clinical development," said Frank Condella, chief executive officer. "Herman brings that right balance of clinical acumen, business sense, regulatory experience, and deep understanding of the continued needs in women's health."
 
Dr. Weiss joins Juniper from Teva Pharmaceutical Industries, Ltd., where he served as Global Medical Director Women's Health and Bone Health. Dr. Weiss was responsible for the global launch of seven products in the contraception, urology, and infertility space, and designed, implemented and oversaw multiple late-stage clinical trials.  He also provided all medical due diligence for business development projects.
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research